Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D T Curiel

Showing results (211-220 of 255) with videos related to

Pageof 26
Sort By:
Nature Biotechnology|September 5, 2001
Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivoP N Reynolds, S A Nicklin, L Kaliberova, et al.
Biochemical and Biophysical Research Communications|December 5, 1998
Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancyT Suzuki, A Piche, K Kasono, et al.
Human Gene Therapy|August 24, 2000
Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluidJ L Blackwell, H Li, J Gomez-Navarro, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 3, 1999
Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vectorB W Tillman, T D de Gruijl, S A Luykx-de Bakker, et al.
Gene Therapy|April 9, 2005
Primary adenovirus-specific cytotoxic T lymphocyte response occurs after viral clearance and liver enzyme elevationJ Chen, A J Zajac, S A McPherson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancerC Rancourt, B E Rogers, B A Sosnowski, et al.
The Journal of Clinical Investigation|March 23, 2000
Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient miceH G Zhang, M Fleck, E R Kern, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 18, 2000
Adenoviral-mediated suicide gene therapy for ovarian cancerR D Alvarez, J Gomez-Navarro, M Wang, et al.
Gynecologic Oncology|June 28, 2001
An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascitesS D Barker, E Casado, J Gomez-Navarro, et al.
Gene Therapy|February 19, 2000
Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus modelJ Gómez-Navarro, J L Contreras, W Arafat, et al.
Pageof 26

Showing results (211-220 of 255) with videos related to

Sort By:
Pageof 26
Nature Biotechnology|September 5, 2001
Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivoP N Reynolds, S A Nicklin, L Kaliberova, et al.
Biochemical and Biophysical Research Communications|December 5, 1998
Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancyT Suzuki, A Piche, K Kasono, et al.
Human Gene Therapy|August 24, 2000
Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluidJ L Blackwell, H Li, J Gomez-Navarro, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 3, 1999
Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vectorB W Tillman, T D de Gruijl, S A Luykx-de Bakker, et al.
Gene Therapy|April 9, 2005
Primary adenovirus-specific cytotoxic T lymphocyte response occurs after viral clearance and liver enzyme elevationJ Chen, A J Zajac, S A McPherson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancerC Rancourt, B E Rogers, B A Sosnowski, et al.
The Journal of Clinical Investigation|March 23, 2000
Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient miceH G Zhang, M Fleck, E R Kern, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 18, 2000
Adenoviral-mediated suicide gene therapy for ovarian cancerR D Alvarez, J Gomez-Navarro, M Wang, et al.
Gynecologic Oncology|June 28, 2001
An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascitesS D Barker, E Casado, J Gomez-Navarro, et al.
Gene Therapy|February 19, 2000
Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus modelJ Gómez-Navarro, J L Contreras, W Arafat, et al.
Pageof 26